Cardiovascular catalyst launched by Novartis

Words by GOLD newsdesk

A new cardiovascular disease (CVD) initiative has been launched by Novartis Pharmaceuticals UK to drive innovation and patient access to home-based digital solutions to prevent future heart attacks and strokes, while tackling health inequalities.


A collaboration with Medtronic, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+ and RYSE Asset Management, the ‘Novartis Biome UK Heart Health Catalyst 2022’ is a world-first investor partnership aiming to “spark a revolution in CVD care”. Investment of up to £3m is available, plus access to a global network of established distribution partners and immediate NHS pilot and validation opportunities.


“I am confident that this bold partnership can deliver significant progress with the UK health system, as well as real change for the seven million people in the UK who are living with CVD,” said Marie-Andrée Gamache, Country President, Novartis Innovative Medicines, UK and Ireland.


The initiative is now open to applications from health-tech start-up founders until 31 August 2022, with particular attention on innovators focusing on major CVD risk factors, non-invasive ways of lipid testing and blood pressure management tools.